Evotec SE
Company Profile
Business description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Contact
Essener Bogen 7
Manfred Eigen Campus
Hamburg22419
DEUT: +49 40560810
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
4,827
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,175.10 | 49.90 | 0.61% |
CAC 40 | 7,536.26 | 33.48 | 0.45% |
DAX 40 | 22,242.45 | 177.94 | 0.81% |
Dow JONES (US) | 40,113.50 | 20.10 | 0.05% |
FTSE 100 | 8,415.25 | 7.81 | 0.09% |
HKSE | 21,980.74 | 70.98 | 0.32% |
NASDAQ | 17,382.94 | 216.90 | 1.26% |
Nikkei 225 | 35,705.74 | 666.59 | 1.90% |
NZX 50 Index | 12,017.84 | 61.37 | 0.51% |
S&P 500 | 5,525.21 | 40.44 | 0.74% |
S&P/ASX 200 | 7,968.20 | 47.70 | 0.60% |
SSE Composite Index | 3,295.06 | 2.23 | -0.07% |